BARTOŠOVÁ, Zdenka and Lumír KREJČÍ. Nucleases in homologous recombination as targets for cancer therapy. FEBS Letters. Amsterdam: Elsevier Science, 2014, vol. 588, No 15, p. 2446-2456. ISSN 0014-5793. Available from: https://dx.doi.org/10.1016/j.febslet.2014.06.010.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Nucleases in homologous recombination as targets for cancer therapy
Name in Czech Nukleázy v homologické rekombinaci jako cíle pro léčbu rakoviny
Authors BARTOŠOVÁ, Zdenka (703 Slovakia, belonging to the institution) and Lumír KREJČÍ (203 Czech Republic, guarantor, belonging to the institution).
Edition FEBS Letters, Amsterdam, Elsevier Science, 2014, 0014-5793.
Other information
Original language English
Type of outcome Article in a journal
Field of Study Genetics and molecular biology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.169
RIV identification code RIV/00216224:14110/14:00073831
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.febslet.2014.06.010
UT WoS 000339535200013
Keywords (in Czech) Genmická integrita, Homologická rekombinace, Nukleáza, Inhibitor, Léčba rakoviny
Keywords in English Genomic integrity; Homologous recombination; Nuclease; Inhibitor; Cancer therapy
Tags EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 29/10/2014 13:47.
Abstract
Genomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous recombination and the role of several nucleases and other recombination factors as suitable targets for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of specific genetic abnormalities of cancer cells that are not present in normal cells and that result in cancer cell lethality. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Links
GAP207/12/2323, research and development projectName: Endonuleazová a translokázová aktivita v restričních-modifikáčních komplexéch typu I
Investor: Czech Science Foundation
GA13-26629S, research and development projectName: SUMO a stability genomu
Investor: Czech Science Foundation
PrintDisplayed: 19/9/2024 06:31